Lisanti资本增长购买Soleno治疗学股份,这是一家开发稀有疾病的治疗的公司。 Lisanti Capital Growth buys shares in Soleno Therapeutics, a company developing treatments for rare diseases.

利桑蒂资本增长有限责任公司最近收购了Soleno治疗药物公司的25,365股股份,该公司是一家开发稀有疾病的治疗的生物制药公司。 Lisanti Capital Growth LLC recently acquired 25,365 shares of Soleno Therapeutics, Inc., a biopharmaceutical company developing treatments for rare diseases. 该公司的主要候选人正在对Prader-Willi综合症进行第三阶段的试验。 The company's lead candidate is in Phase III trials for Prader-Willi Syndrome. Soleno治疗技术公司市场上限为41.9亿美元,“Buy”共识评级为107.10美元,目标价为107.10美元。 Soleno Therapeutics has a market cap of $4.19 billion and a "Buy" consensus rating with a target price of $107.10. 内线Patricia C. Hirano最近出售了266股股票。 Insider Patricia C. Hirano sold 266 shares recently.